4 recruiting, 2 active not recruiting, 1 completed, 1 terminated. 10 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Active not recruiting 2, Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 2, Unknown 1 |
Follow Relapse Multiple Myeloma: new trials by email Literature Review of Relapse Multiple Myeloma trials Research Report on Relapse Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| Melflufen for Elderly Patients With Relapsed Myeloma Melflufen, Dexamethasone - Relapse Multiple Myeloma | Phase 2 | Withdrawn | Fondazione EMN Italy Onlus | 2025-03-26 | 2025-04-01 | |
| MMRC Horizon One: RRMM (MMRC-099) Teclistamab Monotherapy, Teclistamab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Multiple Myeloma Research Consortium | 300 | 2024-11-17 | 2026-06-05 |
| Elranatamab in R/R Multiple Myeloma Elranatamab - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 32 | 2024-03-08 | 2026-08-31 |
| Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Belantamab mafodotin, Carfilzomib, Pomalidomide - Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Recruiting | University of Chicago | 83 | 2023-05-30 | 2026-09-23 |
| Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma Belantamab mafodotin - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Terminated | Medical College of Wisconsin | 1 | 2022-07-19 | 2025-01-28 |
| A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab Daratumumab SC, Clarithromycin, Pomalidomide - Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 11 | 2021-10-28 | 2026-05-20 |
| Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma CAR-BCMA - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Sheba Medical Center | 75 | 2021-09-19 | 2024-01-31 |
| B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma BCMA CAR-T cells - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 10 | 2021-07-01 | 2021-12-09 |
| Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Carfilzomib - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Completed | Ajai Chari | 13 | 2013-09-01 | 2017-06-21 |
Multiple Myeloma (9)
Blood Protein Disorders (9) · Cardiovascular Diseases (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Hemorrhagic Disorders (9) · Hemostatic Disorders (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Plasma Cell (9) · Paraproteinemias (9) · Vascular Diseases (9)
Dexamethasone (4) · carfilzomib (3) · belantamab mafodotin (2) · pomalidomide (2) · Clarithromycin (1) · isatuximab (1) · melflufen (1) · selinexor (1)
Ajai Chari (1) · Fondazione EMN Italy Onlus (1) · Massachusetts General Hospital (1) · Medical College of Wisconsin (1) · Multiple Myeloma Research Consortium (1) · Natalie Callander (1) · Sheba Medical Center (1) · Shenzhen University General Hospital (1) · University of Chicago (1) · Weill Medical College of Cornell University (1)
United States (7) · China (1) · Israel (1) · Italy (1)
Ajai Chari, MD (1) · Benjamin Derman, MD (1) · Hearn J Cho, MD, PhD (1) · Li Yu (1) · Mateo Mejia Saldarriaga, MD (1) · Meera Mohan, MD, MS (1) · Natalie Callander, MD (1) · Noopur Raje, MD (1)